Patents by Inventor Steven Mark Bromidge

Steven Mark Bromidge has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20030069233
    Abstract: Novel sulphonamide derivatives having CNS activity, processes for their preparation and their use as medicaments.
    Type: Application
    Filed: May 29, 2002
    Publication date: April 10, 2003
    Applicant: SmithKline Beecham p.l.c.
    Inventors: Steven Mark Bromidge, Francis David King, Paul Adrian Wyman
  • Patent number: 6423717
    Abstract: Novel sulphonamide derivatives having CNS activity, processes for their preparation and their use as medicaments are disclosed.
    Type: Grant
    Filed: August 21, 2000
    Date of Patent: July 23, 2002
    Assignee: SmithKline Beecham p.l.c.
    Inventors: Steven Mark Bromidge, Francis David King, Paul Adrian Wyman
  • Patent number: 6369060
    Abstract: The invention relates to compounds of formula (I) or a salt thereof wherein X is CH or N; R1 is hydrogen or C1-6 alkyl; R2 and R3 groups are independently C1-6 alkyl, or trifluoromethyl, having pharmacological activity, processes for their preparation, compositions containing them and to their use in the treatment of CNS disorders such as anxiety.
    Type: Grant
    Filed: December 21, 1998
    Date of Patent: April 9, 2002
    Assignee: SmithKline Beecham p.l.c.
    Inventors: Steven Mark Bromidge, Ian Thomson Forbes
  • Publication number: 20020035134
    Abstract: The invention relates to heterocyclic compounds of formula (I) or a salt thereof wherein R1 is hydrogen or C1-6 alkyl; R2, R3 and R4 groups are independently hydrogen, halogen or C1-6 alkyl optionally substituted by one or more fluorine atoms, having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of CNS disorders such as anxiety.
    Type: Application
    Filed: September 6, 2001
    Publication date: March 21, 2002
    Applicant: SmithKline Beecham p.l.c.
    Inventor: Steven Mark Bromidge
  • Publication number: 20010051719
    Abstract: Novel carboxamide derivatives having CNS activity, processes for their preparation and their use as medicaments
    Type: Application
    Filed: May 4, 2001
    Publication date: December 13, 2001
    Applicant: SmithKline Beecham p.l.c.
    Inventors: Steven Mark Bromidge, Francis David King, Paul Adrian Wyman
  • Patent number: 6316450
    Abstract: The invention relates to novel compounds having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of CNS disorders.
    Type: Grant
    Filed: January 10, 2000
    Date of Patent: November 13, 2001
    Assignee: SmithKline Beecham p.l.c.
    Inventors: Steven Mark Bromidge, Stephen Frederick Moss
  • Patent number: 6313145
    Abstract: Indoline derivatives useful as 5HT2C receptor antagonists and methods of using them to treat various CNS disorders are provided.
    Type: Grant
    Filed: December 21, 1998
    Date of Patent: November 6, 2001
    Assignee: SmithKline Beecham p.l.c.
    Inventor: Steven Mark Bromidge
  • Patent number: 6028085
    Abstract: Prodrugs of 5HT.sub.
    Type: Grant
    Filed: September 30, 1998
    Date of Patent: February 22, 2000
    Assignee: SmithKline Beecham plc
    Inventor: Steven Mark Bromidge
  • Patent number: 5981545
    Abstract: A compound of formula (I) or a pharmaceutically acceptable salt thereof: ##STR1## in which one of X and Y represents hydrogen and the other represents Z, where Z is a group ##STR2## in which Q represents a 3-membered divalent residue completing a 5-membered aromatic ring and comprises zero, one or two nitrogen atoms, Q being optionally C-substituted by a group R.sub.1 selected from halogen, CN, OR.sub.2, SR.sub.2, N(R.sub.2).sub.2, NHCOR.sub.2, NHCOOCH.sub.3, NHCOOC.sub.2 H.sub.5, NHOR.sub.2, N.sub.3, NHNH.sub.2, NO.sub.2, COR.sub.2, COR.sub.3, C.sub.2-4 alkenyl, C.sub.2-4 alkynyl, cyclopropyl or C.sub.1-2 alkyl optionally substituted with OR.sub.2, N(R.sub.2).sub.2, SR.sub.2, CO.sub.2 R.sub.2, CON(R.sub.2).sub.2 or one, two or three halogen atoms, in which each R.sub.2 is independently hydrogen or C.sub.1-2 alkyl and R.sub.3 is OR.sub.2, NH.sub.2 or NHR.sub.2 ; r represents an integer of 2 or 3, s represents an integer of 1 or 2 and t represents 0 or 1; R.sub.a and R.sub.
    Type: Grant
    Filed: October 4, 1990
    Date of Patent: November 9, 1999
    Assignee: Beecham Group p.l.c.
    Inventors: Sarah Margaret Jenkins, Harry John Wadsworth, Barry Sidney Orlek, Steven Mark Bromidge
  • Patent number: 5808075
    Abstract: A process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof wherein R.sub.1 represents (a) in which r represents an integer of 2 to 4, s represents 1 or 2 and t represents 0 or 1; R.sub.2 is a group OR.sub.4, where R.sub.4 is C.sub.1-4 alkyl, C.sub.2-4 alkenyl or C.sub.2-4 alkynyl or a group OCOR.sub.5 where R.sub.5 is hydrogen or R.sub.4 ; and R.sub.3 is CN; said process comprising reacting a compound of formula (II) wherein R.sub.1 ' is R.sub.1 or a group convertible thereto, and R.sub.3 ' is an electron withdrawing group, with a source of nitrous acid, and thereafter converting the resulting .dbd.NOH group to .dbd.NR.sub.2 wherein R.sub.2 is as defined in formula (I), converting R.sub.1 ' and R.sub.3 ' when other than R.sub.1 and R.sub.3 to R.sub.1 and R.sub.3, and thereafter optionally forming a pharmaceutically acceptable salt.
    Type: Grant
    Filed: November 12, 1996
    Date of Patent: September 15, 1998
    Inventors: Steven Mark Bromidge, Martyn Voyle, Erol Ali Faruk, Mark Jason Hughes, John Kitteringham, Gary Thomas Borrett
  • Patent number: 5773619
    Abstract: A process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof: ##STR1## wherein R.sub.1 represents ##STR2## in which r represents an integer of 2 to 4, s represents 1 or 2 and t represents 0 or 1;R.sub.2 is a group OR.sub.4, where R.sub.4 is C.sub.1-4 alkyl, C.sub.2-4 alkenyl or C.sub.2-4 alkynyl or a group OCOR.sub.5 where R.sub.5 is hydrogen or R.sub.4 ; andR.sub.3 is CN;said process comprising reacting a compound of formula (II): ##STR3## wherein R.sub.1 ' is R.sub.1 or a group convertible thereto, and R.sub.3 ' is an electron withdrawing group, with a source of nitrous acid, and thereafter converting the resulting .dbd.NOH group to .dbd.NR.sub.2 wherein R.sub.2 is as defined in formula (I), converting R.sub.1 ' and R.sub.3 ' when other than R.sub.1 and R.sub.3 to R.sub.1 and R.sub.3, and thereafter optionally forming a pharmaceutically acceptable salt.
    Type: Grant
    Filed: May 12, 1995
    Date of Patent: June 30, 1998
    Assignee: SmithKline Beecham p.l.c.
    Inventors: Steven Mark Bromidge, Martyn Voyle, Erol Ali Faruk, Mark Jason Hughes, John Kitteringham, Gary Thomas Borrett
  • Patent number: 5675007
    Abstract: A compound of formula (I) or a pharmaceutically acceptable salt thereof (I) wherein R.sub.1 represents (a), R.sub.2 is a group OCH.sub.3, and R.sub.3 is cyano, for use in the treatment and/or prophylaxis of dementia in mammals.
    Type: Grant
    Filed: November 12, 1996
    Date of Patent: October 7, 1997
    Assignee: SmithKline Beecham p.l.c.
    Inventors: John Keogh, Gary Thomas Borrett, Steven Mark Bromidge, Erol Ali Faruk, Mark Jason Hughes, John Kitteringham, Martyn Voyle